Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28706306
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Ligand-induced type II interleukin-4 receptor dimers are sustained by rapid
re-association within plasma membrane microcompartments
#MMPMID28706306
Richter D
; Moraga I
; Winkelmann H
; Birkholz O
; Wilmes S
; Schulte M
; Kraich M
; Kenneweg H
; Beutel O
; Selenschik P
; Paterok D
; Gavutis M
; Schmidt T
; Garcia KC
; Müller TD
; Piehler J
Nat Commun
2017[Jul]; 8
(?): 15976
PMID28706306
show ga
The spatiotemporal organization of cytokine receptors in the plasma membrane is
still debated with models ranging from ligand-independent receptor
pre-dimerization to ligand-induced receptor dimerization occurring only after
receptor uptake into endosomes. Here, we explore the molecular and cellular
determinants governing the assembly of the type II interleukin-4 receptor, taking
advantage of various agonists binding the receptor subunits with different
affinities and rate constants. Quantitative kinetic studies using artificial
membranes confirm that receptor dimerization is governed by the two-dimensional
ligand-receptor interactions and identify a critical role of the transmembrane
domain in receptor dimerization. Single molecule localization microscopy at
physiological cell surface expression levels, however, reveals efficient
ligand-induced receptor dimerization by all ligands, largely independent of
receptor binding affinities, in line with the similar STAT6 activation potencies
observed for all IL-4 variants. Detailed spatiotemporal analyses suggest that
kinetic trapping of receptor dimers in actin-dependent microcompartments sustains
robust receptor dimerization and signalling.
|Actin Cytoskeleton
[MESH]
|Cell Compartmentation
[MESH]
|Cell Membrane/*metabolism
[MESH]
|Dimerization
[MESH]
|HeLa Cells
[MESH]
|Humans
[MESH]
|Ligands
[MESH]
|Receptors, Interleukin-4, Type II/agonists/*metabolism
[MESH]